Back
GRAIL class action targets alleged omissions around NHS-Galleri trial results

GRAIL class action targets alleged omissions around NHS-Galleri trial results

Investors who bought GRAIL common stock between May 13, 2025 and Feb. 19, 2026 face an Aug. 4, 2026 deadline to seek lead plaintiff status in the proposed case.

Fact Check
Both components of the claim are directly confirmed by their respective primary press releases. The BFA Law release confirms a filed federal securities class action targeting Hub Group's 2025 restatement and control failures, and the Grabar Law Office release confirms an active investigation into potential fiduciary-duty (derivative-style) claims for long-term Hub Group holders. The underlying restatement facts are independently corroborated by Trucking Dive and Hub Group's own SEC 8-K filing, which describe the understatement of purchased transportation costs and accounts payable.
Summary

GRAIL, Inc. is facing a proposed securities class action alleging it misled investors about the state of its NHS-Galleri trial and the likelihood that the study could demonstrate a statistically significant reduction in late-stage cancers within its three-year follow-up period. The proposed class covers investors who purchased or acquired GRAIL common stock between May 13, 2025 and Feb. 19, 2026, with an Aug. 4, 2026 deadline to apply to be appointed lead plaintiff. The complaint alleges the company made materially false and misleading statements or concealed adverse facts after revealing top-line results from the trial’s first screening round. It claims defendants later acknowledged that, as executed within the three-year follow-up period, the trial was insufficient to show whether the primary endpoint of reducing Stage III-IV cancers was achievable, while repeatedly declining to provide more detailed topline results or other NHS-Galleri data. On Feb. 19, 2026, GRAIL announced results from the NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test, stating that the primary endpoint of statistically significant Stage III-IV reduction was not observed. The lawsuit contends that disclosure exposed the limits of the trial design and triggered a significant drop in GRAIL’s stock price.

Terms & Concepts
  • lead plaintiff: An investor appointed by the court to act on behalf of the proposed class in a securities lawsuit.
  • top-line results: Initial high-level findings from a clinical trial released before fuller underlying data are published.
  • primary endpoint: The main outcome a clinical trial is designed to measure to determine whether it met its objective.